Tumor dormancy and the angiogenic switch: Possible implications of bone marrow-derived cells

Current Pharmaceutical Design

Volumn 20, Issue 30, 2014, Pages 4920-4933

  Shaked, Yuval ^a   Mcallister, Sandra ^b   Fainaru, Ofer ^a,c   Almog, Nava ^d  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HILLEL YAFFE MEDICAL CENTER   (Israel)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenic switch; Bone marrow derived cells; Pro angiogenic; Tumor dormancy; Tumor host crosstalk

Indexed keywords

ANGIOPOIETIN RECEPTOR; ANTINEOPLASTIC AGENT; CELL ADHESION MOLECULE; CYTOKINE;

ANGIOGENESIS; BONE MARROW CELL; CANCER CELL; DENDRITIC CELL; DISEASE COURSE; DORMANCY; ENDOTHELIAL PROGENITOR CELL; FIBROBLAST; HUMAN; IMMUNE SYSTEM; LYMPHOCYTE; MACROPHAGE; MAST CELL; MICROENVIRONMENT; MONOCYTE; NEOPLASM; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STROMA CELL; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR DORMANCY; TUMOR GROWTH; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CELL COMMUNICATION; HEMANGIOCYTE; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; TUMOR CELL; ANIMAL; MOUSE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; BONE MARROW CELLS; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84906252921     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612819666131125153536     Document Type: Review

References (203)

1. Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7(11): 834-846.
2. Almog N. Molecular mechanisms underlying tumor dormancy. Cancer Lett 2010; 294(2): 139-146.
3. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427(6977): 787.
4. Uhr JW, Scheuermann RH, Street NE, Vitetta ES. Cancer dormancy: opportunities for new therapeutic approaches. Nat Med 1997; 3(5): 505-509.
5. Weinberg RA. The many faces of tumor dormancy. APMIS 2008; 116(7-8): 548-551.
6. Vessella RL, Pantel K, Mohla S. Tumor cell dormancy: an NCI workshop report. Cancer Biol Ther 2007; 6(9): 1496-1504.
7. Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer 2008; 123(9): 1991-2006.
8. Klein CA. Framework models of tumor dormancy from patient-derived observations. Curr Opin Genet Dev 2011; 21(1): 42-49.
9. Fehm T, Mueller V, Marches R, et al. Tumor cell dormancy: implications for the biology and treatment of breast cancer. APMIS 2008; 116(7-8): 742-753.
10. Paez D, Labonte MJ, Bohanes P, et al. Cancer dormancy: a model of early dissemination and late cancer recurrence. Clin Cancer Res 2012; 18(3): 645-653.
11. Black WC, Welch HG. Advances in diagnostic imaging and over-estimations of disease prevalence and the benefits of therapy. N Engl J Med 1993; 328(17): 1237-1243.
12. Goss PE, Chambers AF. Does tumour dormancy offer a therapeutic target? Nat Rev Cancer 2010; 10(12): 871-877.
13. Bissell MJ, Hines WC. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011; 17(3): 320-329.
14. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144(5): 646-674.
15. Teng MW, Swann JB, Koebel CM, Schreiber RD, Smyth MJ. Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol 2008; 84(4): 988-993.
16. Quesnel B. Tumor dormancy and immunoescape. APMIS 2008; 116(7-8): 685-694.
17. Favaro E, Amadori A, Indraccolo S. Cellular interactions in the vascular niche: implications in the regulation of tumor dormancy. APMIS 2008; 116(7-8): 648-659.
18. Aguirre-Ghiso JA. The problem of cancer dormancy: understanding the basic mechanisms and identifying therapeutic opportunities. Cell Cycle 2006; 5(16): 1740-1743.
19. Barkan D, Green JE, Chambers AF. Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth. Eur J Cancer 2010; 46(7): 1181-1188.
20. Chambers AF. Influence of diet on metastasis and tumor dormancy. Clin Exp Metastasis 2009; 26(1): 61-66.
21. Cervi D, Pak B, Venier NA, et al. Micronutrients attenuate progression of prostate cancer by elevating the endogenous inhibitor of angiogenesis, platelet factor-4. BMC Cancer 2010; 10: 258.
22. Castano Z, Tracy K, McAllister SS. The tumor macroenvironment and systemic regulation of breast cancer progression. Int J Dev Biol 2011; 55(7-9): 889-897.
23. Udagawa T. Tumor dormancy of primary and secondary cancers. APMIS 2008; 116(7-8): 615-628.
24. Almog N. Genes and Regulatory Pathways Involved in Persistence of Dormant Micro-tumors. Adv Exp Med Biol 2013.
25. Quesnel B. Dormant tumor cells as a therapeutic target? Cancer Lett 2008; 267(1): 10-17.
26. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009; 6(6): 339-351.
27. Demicheli R, Retsky MW, Hrushesky WJ, Baum M. Tumor dormancy and surgery-driven interruption of dormancy in breast cancer: learning from failures. Nat Clin Pract Oncol 2007; 4(12): 699-710.
28. Demicheli R, Terenziani M, Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Local recurrences following mastectomy: support for the concept of tumor dormancy. J Natl Cancer Inst 1994; 86(1): 45-48.
29. Retsky M, Rogers R, Demicheli R, et al. NSAID analgesic ketoro-lac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat 2012; 134(2): 881-888.
30. Brackstone M, Townson JL, Chambers AF. Tumour dormancy in breast cancer: an update. Breast Cancer Res 2007; 9(3): 208.
31. Bednarz-Knoll N, Alix-Panabieres C, Pantel K. Clinical relevance and biology of circulating tumor cells. Breast Cancer Res 2011; 13(6): 228.
32. Franssila KO, Harach HR. Occult papillary carcinoma of the thyroid in children and young adults. A systemic autopsy study in Finland. Cancer 1986; 58(3): 715-719.
33. Harach HR, Franssila KO, Wasenius VM. Occult papillary carcinoma of the thyroid. A normal finding in Finland. A systematic autopsy study. Cancer 1985; 56(3): 531-538.
34. Welch HG, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102(9): 605-613.
35. Montie JE, Wood DP, Jr., Pontes JE, Boyett JM, Levin HS. Adeno-carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. Cancer 1989; 63(2): 381-385.
36. Almog N, Henke V, Flores L, et al. Prolonged dormancy of human liposarcoma is associated with impaired tumor angiogenesis. FASEB J 2006; 20(7): 947-949.
37. Naumov GN, Bender E, Zurakowski D, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 2006; 98(5): 316-325.
38. Almog N, Klement G. Platelet Proteome and Tumor Dormancy: Can Platelets Content Serve as Predictive Biomarkers for Exit of Tumors from Dormancy? Cancers 2010; 2: 842-858.
39. Cervi D, Yip TT, Bhattacharya N, et al. Platelet-associated PF-4 as a biomarker of early tumor growth. Blood 2008; 111(3): 1201-1207.
40. Klement GL, Yip TT, Cassiola F, et al. Platelets actively sequester angiogenesis regulators. Blood 2009; 113(12): 2835-2842.
41. Almog N, Ma L, Schwager C, et al. Consensus Micro RNAs Governing the Switch of Dormant Tumors to the Fast-Growing Angio-genic Phenotype. PlosOne 2012.
42. Almog N, Ma L, Raychowdhury R, et al. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype. Cancer Res 2009; 69(3): 836-844.
43. Kim RS, Avivar-Valderas A, Estrada Y, et al. Dormancy signatures and metastasis in estrogen receptor positive and negative breast cancer. PLoS One 2012; 7(4): e35569.
44. Izraely S, Sagi-Assif O, Klein A, et al. The metastatic microenvi-ronment: Brain-residing melanoma metastasis and dormant micro-metastasis. Int J Cancer 2012; 131(5): 1071-1082.
45. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003; 3(3): 219-231.
46. McAllister SS, Gifford AM, Greiner AL, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133(6): 994-1005.
47. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285(21): 1182-1186.
48. Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136(2): 261-276.
49. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. Leukemia 2007; 21(1): 44-52.
50. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992; 3(2): 65-71.
51. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1(1): 27-31.
52. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3(6): 401-410.
53. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamical theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999; 59(19): 4770-4775.
54. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86(3): 353-364.
55. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer 1996; 32A(14): 2386-2393.
56. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15(1): 50-65.
57. Indraccolo S, Favaro E, Amadori A. Dormant tumors awaken by a short-term angiogenic burst: the spike hypothesis. Cell Cycle 2006; 5(16): 1751-1755.
58. Indraccolo S, Minuzzo S, Masiero M, Amadori A. Ligand-driven activation of the notch pathway in T-ALL and solid tumors: why Not(ch)? Cell Cycle 2010; 9(1): 80-85.
59. Indraccolo S, Minuzzo S, Masiero M, et al. Cross-talk between tumor and endothelial cells involving the Notch3-Dll4 interaction marks escape from tumor dormancy. Cancer Res 2009; 69(4): 1314-1323.
60. Indraccolo S, Stievano L, Minuzzo S, et al. Interruption of tumor dormancy by a transient angiogenic burst within the tumor micro-environment. Proc Natl Acad Sci U S A 2006; 103(11): 4216-4221.
61. Baeriswyl V, Christofori G. The angiogenic switch in carcinogene-sis. Semin Cancer Biol 2009; 19(5): 329-337.
62. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-2049.
63. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964-967.
64. Asahara T, Masuda H, Takahashi T, et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogene-sis in physiological and pathological neovascularization. Circ Res 1999; 85(3): 221-228.
65. Petit I, Jin D, Rafii S. The SDF-1-CXCR4 signaling pathway: a molecular hub modulating neo-angiogenesis. Trends Immunol 2007; 28(7): 299-307.
66. Grunewald M, Avraham I, Dor Y, et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006; 124(1): 175-189.
67. Jin DK, Shido K, Kopp HG, et al. Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes. Nat Med 2006; 12(5): 557-567.
68. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999 Jul 15; 18(14): 3964-3972.
69. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer 2006; 6(11): 835-845.
70. Heil M, Ziegelhoeffer T, Mees B, Schaper W. A different outlook on the role of bone marrow stem cells in vascular growth: bone marrow delivers software not hardware. Circ Res 2004; 94(5): 573-574.
71. Machein MR, Renninger S, de Lima-Hahn E, Plate KH. Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. Brain Pathol 2003; 13(4): 582-597.
72. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothe-lium and are not needed for tumor growth. Proc Natl Acad Sci U S A 2008; 105(18): 6620-6625.
73. Gothert JR, Gustin SE, van Eekelen JA, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood 2004; 104(6): 1769-1777.
74. Rajantie I, Ilmonen M, Alminaite A, Ozerdem U, Alitalo K, Salven P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004; 104(7): 2084-2086.
75. Kerbel RS, Benezra R, Lyden DC, et al. Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas. Proc Natl Acad Sci U S A 2008; 105(34): E54; author reply E5.
76. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med 2005; 11(3): 261-262.
77. Horrevoets AJ. Angiogenic monocytes: another colorful blow to endothelial progenitors. Am J Pathol 2009; 174(5): 1594-1596.
78. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006; 313(5794): 1785-1787.
79. Shaked Y, Kerbel RS. Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. Cancer Res 2007; 67(15): 7055-7058.
80. De Palma M, Naldini L. Tie2-expressing monocytes (TEMs): novel targets and vehicles of anticancer therapy? Biochim Biophys Acta 2009; 1796(1): 5-10.
81. De Palma M, Venneri MA, Galli R, et al. Tie2 identifies a hema-topoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005; 8(3): 211-226.
82. Augustin HG, Koh GY, Thurston G, Alitalo K. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol 2009; 10(3): 165-177.
83. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res 2009; 69(4): 1324-1333.
84. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood 2007; 109(12): 5276-5285.
85. Matsubara T, Kanto T, Kuroda S, et al. TIE2-expressing mono-cytes as a diagnostic marker for hepatocellular carcinoma correlated with angiogenesis. Hepatology 2012 Jul 19.
86. Goede V, Coutelle O, Shimabukuro-Vornhagen A, et al. Analysis of Tie2-expressing monocytes (TEM) in patients with colorectal cancer. Cancer Invest 2012; 30(3): 225-230.
87. Fainaru O, Hantisteanu S, Hallak M. Immature myeloid cells accumulate in mouse placenta and promote angiogenesis. Am J Ob-stet Gynecol 2011; 204(6): 544 e18-544 e23.
88. Mei-Dan E, Fainaru O, Hantisteanu S, Shavit T, Ellenbogen A, Hallak M. Proangiogenic immature myeloid cells populate the human placenta and their presence correlates with placental and birthweight. Am J Obstet Gynecol 2012; 207(2): 141e1-141e5.
89. Ohki S, Shibata M, Gonda K, et al. Circulating myeloid-derived suppressor cells are increased and correlate to immune suppression, inflammation and hypoproteinemia in patients with cancer. Oncol Rep 2012; 28(2): 453-458.
90. Ostrand-Rosenberg S, Sinha P. Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 2009; 182(8): 4499-4506.
91. Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004; 6(4): 409-421.
92. Carrer A, Moimas S, Zacchigna S, et al. Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth. Cancer Res 2012; 72(24): 6371-6381.
93. Zacchigna S, Pattarini L, Zentilin L, et al. Bone marrow cells recruited through the neuropilin-1 receptor promote arterial formation at the sites of adult neoangiogenesis in mice. J Clin Invest 2008; 118(6): 2062-2075.
94. Shojaei F, Wu X, Malik AK, et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007; 25(8): 911-920.
95. Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11(7): 856-861.
96. Toh B, Wang X, Keeble J, et al. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor. PLoS Biol 2011; 9(9): e1001162.
97. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13(6): 591-599.
98. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5(12): 953-964.
99. Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta 2009; 1796(1): 11-18.
100. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 2001; 193(6): 727-740.
101. Du R, Lu KV, Petritsch C, et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008; 13(3): 206-220.
102. Cohen-Kaplan V, Naroditsky I, Zetser A, Ilan N, Vlodavsky I, Doweck I. Heparanase induces VEGF C and facilitates tumor lym-phangiogenesis. Int J Cancer 2008; 123(11): 2566-2573.
103. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392(6673): 245-252.
104. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008; 222: 162-179.
105. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol 2004; 4(12): 941-952.
106. Ghiringhelli F, Puig PE, Roux S, et al. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med 2005; 202(7): 919-929.
107. Sica A, Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 2007; 117(5): 1155-1166.
108. Gabrilovich D, Ishida T, Oyama T, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998; 92(11): 4150-4166.
109. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004; 10(9): 950-958.
110. Coukos G, Benencia F, Buckanovich RJ, Conejo-Garcia JR. The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer 2005; 92(7): 1182-1187.
111. Fainaru O, Adini A, Benny O, et al. Dendritic cells support angio-genesis and promote lesion growth in a murine model of endome-triosis. Faseb J 2008; 22(2): 522-529.
112. Plaks V, Birnberg T, Berkutzki T, et al. Uterine DCs are crucial for decidua formation during embryo implantation in mice. J Clin Invest 2008; 118(12): 3954-3965.
113. Nakai K, Fainaru O, Bazinet L, Pakneshan P, Benny O, Pravda E, et al. Dendritic cells augment choroidal neovascularization. Invest Ophthalmol Vis Sci 2008; 49(8): 3666-3670.
114. Fainaru O, Almog N, Yung CW, et al. Tumor growth and angio-genesis are dependent on the presence of immature dendritic cells. FASEB J 2010; 24(5): 1411-1418.
115. Chen CC, Grimbaldeston MA, Tsai M, Weissman IL, Galli SJ. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 2005; 102(32): 11408-11413.
116. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 2006; 1088: 78-99.
117. Amini RM, Aaltonen K, Nevanlinna H, et al. Mast cells and eosi-nophils in invasive breast carcinoma. BMC Cancer 2007; 7: 165.
118. Ch'ng S, Wallis RA, Yuan L, Davis PF, Tan ST. Mast cells and cutaneous malignancies. Mod Pathol 2006; 19(1): 149-159.
119. Coussens LM, Raymond WW, Bergers G, et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcino-genesis. Genes Dev 1999; 13(11): 1382-1397.
120. Maltby S, Khazaie K, McNagny KM. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. Biochim Biophys Acta 2009; 1796(1): 19-26.
121. Poole TJ, Zetter BR. Stimulation of rat peritoneal mast cell migration by tumor-derived peptides. Cancer Res 1983; 43(12 Pt 1): 5857-5861.
122. Zhang W, Stoica G, Tasca SI, Kelly KA, Meininger CJ. Modulation of tumor angiogenesis by stem cell factor. Cancer Res 2000; 60(23): 6757-6762.
123. Ribatti D, Vacca A, Nico B, Crivellato E, Roncali L, Dammacco F. The role of mast cells in tumour angiogenesis. Br J Haematol 2001; 115(3): 514-521.
124. Dabiri S, Huntsman D, Makretsov N, et al. The presence of stromal mast cells identifies a subset of invasive breast cancers with a favorable prognosis. Mod Pathol 2004; 17(6): 690-695.
125. Hiratsuka S, Nakamura K, Iwai S, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002; 2(4): 289-300.
126. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005; 438(7069): 820-827.
127. Kaplan RN, Psaila B, Lyden D. Niche-to-niche migration of bone-marrow-derived cells. Trends Mol Med 2007; 13(2): 72-81.
128. Dawson MR, Duda DG, Chae SS, Fukumura D, Jain RK. VEGFR1 activity modulates myeloid cell infiltration in growing lung metas-tases but is not required for spontaneous metastasis formation. PLoS One 2009; 4(9): e6525.
129. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319(5860): 195-198.
130. Badiavas EV, Abedi M, Butmarc J, Falanga V, Quesenberry P. Participation of bone marrow derived cells in cutaneous wound healing. J Cell Physiol 2003; 196(2): 245-250.
131. Fathke C, Wilson L, Hutter J, et al. Contribution of bone marrow-derived cells to skin: collagen deposition and wound repair. Stem Cells 2004; 22(5): 812-822.
132. Shintani S, Murohara T, Ikeda H, et al. Mobilization of endothelial progenitor cells in patients with acute myocardial infarction. Circulation 2001; 103(23): 2776-2779.
133. Wright DE, Wagers AJ, Gulati AP, Johnson FL, Weissman IL. Physiological migration of hematopoietic stem and progenitor cells. Science 2001; 294(5548): 1933-1936.
134. Kondo M, Wagers AJ, Manz MG, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol 2003; 21: 759-806.
135. Tsou CL, Peters W, Si Y, et al. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and recruitment to inflammatory sites. J Clin Invest 2007; 117(4): 902-909.
136. Serbina NV, Shi C, Pamer EG. Monocyte-mediated immune defense against murine Listeria monocytogenes infection. Adv Immunol 2012; 113: 119-134.
137. Martin C, Burdon PC, Bridger G, Gutierrez-Ramos JC, Williams TJ, Rankin SM. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone marrow and their return following senescence. Immunity 2003; 19(4): 583-593.
138. Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from mur-ine bone marrow. J Clin Invest 2010; 120(7): 2423-2431.
139. Kopp HG, Ramos CA, Rafii S. Contribution of endothelial progenitors and proangiogenic hematopoietic cells to vascularization of tumor and ischemic tissue. Curr Opin Hematol 2006; 13(3): 175-181.
140. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14(3): 263-273.
141. Okazaki T, Ebihara S, Asada M, Kanda A, Sasaki H, Yamaya M. Granulocyte colony-stimulating factor promotes tumor angiogene-sis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 2006; 18(1): 1-9.
142. Orimo A, Gupta PB, Sgroi DC, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and an-giogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005; 121(3): 335-348.
143. Christopher MJ, Rao M, Liu F, Woloszynek JR, Link DC. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011; 208(2): 251-260.
144. Chow A, Lucas D, Hidalgo A, et al. Bone marrow CD169+ macro-phages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011; 208(2): 261-271.
145. Winkler IG, Sims NA, Pettit AR, et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010; 116(23): 4815-4828.
146. Shi C, Jia T, Mendez-Ferrer S, et al. Bone marrow mesenchymal stem and progenitor cells induce monocyte emigration in response to circulating toll-like receptor ligands. Immunity 2011; 34(4): 590-601.
147. Peterson JE, Zurakowski D, Italiano JE, Jr., et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients. Angi-ogenesis 2012; 15(2): 265-273.
148. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. J Biol Chem 2000; 275(3): 1521-1524.
149. Battinelli EM, Markens BA, Italiano JE, Jr. Release of angiogene-sis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood 2011; 118(5): 1359-1369.
150. Italiano JE, Jr., Richardson JL, Patel-Hett S, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008; 111(3): 1227-1233.
151. Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta 2011; 1815(2): 189-196.
152. Kuznetsov HS, Marsh T, Markens BA, et al. Identification of lumi-nal breast cancers that establish a tumor-supportive macroenviron-ment defined by proangiogenic platelets and bone marrow-derived cells. Cancer Discov 2012; 2(12): 1150-1165.
153. Taucher S, Salat A, Gnant M, et al. Impact of pretreatment throm-bocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89(6): 1098-1106.
154. Stone RL, Nick AM, McNeish IA, et al. Paraneoplastic thrombocy-tosis in ovarian cancer. N Engl J Med 2012; 366(7): 610-618.
155. Gisterek I, Matkowski R, Lacko A, et al. Serum vascular endothe-lial growth factors a, C and d in human breast tumors. Pathol Oncol Res 2010; 16(3): 337-344.
156. Peinado H, Aleckovic M, Lavotshkin S, et al. Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phe-notype through MET. Nat Med 2012; 18(6): 883-891.
157. Swirski FK, Nahrendorf M, Etzrodt M, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science 2009; 325(5940): 612-616.
158. Cortez-Retamozo V, Etzrodt M, Newton A, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci U S A 2012; 109(7): 2491-2496.
159. Elkabets M, Gifford AM, Scheel C, et al. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J Clin Invest 2011; 121(2): 784-799.
160. Bateman A, Bennett HP. The granulin gene family: from cancer to dementia. Bioessays 2009; 31(11): 1245-1254.
161. He Z, Bateman A. Progranulin (granulin-epithelin precursor, PC-cell-derived growth factor, acrogranin) mediates tissue repair and tumorigenesis. J Mol Med (Berl) 2003; 81(10): 600-612.
162. Calvi LM, Adams GB, Weibrecht KW, et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425(6960): 841-846.
163. Nilsson SK, Johnston HM, Whitty GA, et al. Osteopontin, a key component of the hematopoietic stem cell niche and regulator of primitive hematopoietic progenitor cells. Blood 2005; 106(4): 1232-1239.
164. Stier S, Ko Y, Forkert R, et al. Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med 2005; 201(11): 1781-1791.
165. McAllister SS, Weinberg RA. Tumor-host interactions: a far-reaching relationship. J Clin Oncol 2010; 28(26): 4022-4028.
166. Gohongi T, Fukumura D, Boucher Y, et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat Med 1999; 5(10): 1203-1208.
167. Kang SY, Halvorsen OJ, Gravdal K, et al. Prosaposin inhibits tumor metastasis via paracrine and endocrine stimulation of stromal p53 and Tsp-1. Proc Natl Acad Sci U S A 2009; 106(29): 12115-12120.
168. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994; 79(2): 315-328.
169. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88(2): 277-285.
170. Volpert OV, Lawler J, Bouck NP. A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1. Proc Natl Acad Sci U S A 1998; 95(11): 6343-6348.
171. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007; 104(43): 17069-17074.
172. Schuch G, Heymach JV, Nomi M, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endo-thelial progenitor cells. Cancer Res 2003; 63(23): 8345-8350.
173. Capillo M, Mancuso P, Gobbi A, et al. Continuous infusion of endostatin inhibits differentiation, mobilization, and clonogenic potential of endothelial cell progenitors. Clin Cancer Res 2003; 9(1): 377-382.
174. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350(23): 2335-2342.
175. Robert NJ, Saleh MN, Paul D, et al. Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial. Clin Breast Cancer 2011; 11(2): 82-92.
176. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-2550.
177. Lai GG, Penson RT. Bevacizumab and ovarian cancer. Drugs Today (Barc) 2011; 47(9): 669-681.
178. Wong ET, Gautam S, Malchow C, Lun M, Pan E, Brem S. Bevaci-zumab for recurrent glioblastoma multiforme: a meta-analysis. J Natl Compr Canc Netw 2011; 9(4): 403-407.
179. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357(26): 2666-2676.
180. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4): 378-390.
181. Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009; 27(22): 3584-3590.
182. Folkins C, Shaked Y, Man S, et al. Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endo-thelial growth factor and stromal-derived factor 1. Cancer Res 2009; 69(18): 7243-7251.
183. Benayoun L, Gingis-Velitski S, Voloshin T, et al. Tumor-initiating cells of various tumor types exhibit differential angiogenic properties and react differently to antiangiogenic drugs. Stem Cells 2012; 30(9): 1831-1841.
184. Eyler CE, Rich JN. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J Clin Oncol 2008; 26(17): 2839-2845.
185. Ponti D, Costa A, Zaffaroni N, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005; 65(13): 5506-5511.
186. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006; 66(16): 7843-7848.
187. Calabrese C, Poppleton H, Kocak M, et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007; 11(1): 69-82.
188. Kubisch R, Meissner L, Krebs S, et al. A Comprehensive Gene Expression Analysis of Resistance Formation upon Metronomic Cyclophosphamide Therapy. Transl Oncol 2013; 6(1): 1-9.
189. Sierra JR, Cepero V, Giordano S. Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol Cancer 2010; 9: 75.
190. Moreno Garcia V, Basu B, Molife LR, Kaye SB. Combining antiangiogenics to overcome resistance: rationale and clinical experience. Clin Cancer Res 2012; 18(14): 3750-3761.
191. Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One 2009; 4(11): e7669.
192. Mazzieri R, Pucci F, Moi D, et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011; 19(4): 512-526.
193. Shaked Y, Bertolini F, Man S, et al. Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. Cancer Cell 2005; 7(1): 101-111.
194. Shaked Y, Emmenegger U, Man S, et al. Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. Blood 2005; 106(9): 3058-3061.
195. Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res 2009; 15(1): 267-273.
196. Bertolini F, Mancuso P, Braidotti P, Shaked Y, Kerbel RS. The multiple personality disorder phenotype(s) of circulating endothe-lial cells in cancer. Biochim Biophys Acta 2009; 1796(1): 27-32.
197. Calleri A, Bono A, Bagnardi V, et al. Predictive Potential of Angi-ogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus Bevacizumab. Clin Cancer Res 2009; 15(24): 7652-7657.
198. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclo-phosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008; 26(30): 4899-4905.
199. Ko AH, Venook AP, Bergsland EK, et al. A phase II study of bevacizumab plus erlotinib for gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 2010; 66(6): 1051-1057.
200. Farace F, Gross-Goupil M, Tournay E, et al. Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with ty-rosine kinase inhibitors. Br J Cancer 2011; 104(7): 1144-1150.
201. Allegrini G, Di Desidero T, Barletta MT, et al. Clinical, pharma-cokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers. Angiogenesis 2012; 15(2): 275-286.
202. Rossi E, Fassan M, Aieta M, et al. Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer. Br J Cancer 2012; 107(8): 1286-1294.
203. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012 Jul 31.